Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Serious Adverse Events and Monitoring Requirements While rare, serious adverse events require careful monitoring and patient selection ^6
Handling: Strict laboratory conditions required
It leads to higher insulin levels, which promote fat storage , particularly around the abdomen
Where Do We Go from Here
Investor Takeaway For investors seeking exposure to the GLP-1 boom in India, the key is to identify companies with proven capabilities in: Peptide synthesis Sterile injectable manufacturing Global regulatory compliance CDMO services with US/EU clients Recommended Monitoring: R&D updates and capacity expansions Any tie-ups with global GLP-1 players Clinical trial progress for biosimilar versions Regulatory approvals (USFDA, EMA) Export data to key markets (USA, Canada, China) Conclusion The weight loss drug boom is changing global healthcare and creating a huge business opportunity for Indian pharma companies
US$ 28.81
US$ 24.14
US$ 25.12
US$ 29.80
US$ 20.36
US$ 25.14
US$ 23.79
